# 4DMT Announces New Employment Inducement Grants
- Published: 2026-11-13
- Author: [BiotechNews.io](https://biotechnews.io/author/biotechnews-io.md)
- Topics: [News](https://biotechnews.io/news.md)
- Source: https://biotechnews.io/news/4dmt-announces-new-employment-inducement-grants/
- Publication: Biotech News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://biotechnews.io/editorial-policy/
EMERYVILLE, Calif., Nov. 13, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on November 10, 2026, the compensation committee of the Company’s board of directors granted one new non-executive employee 21,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
**About 4DMT**
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
CONTACT: Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
## Related
- [Kura Oncology to Participate in Two Investor Conferences in November](https://biotechnews.io/news/kura-oncology-to-participate-in-two-investor-conferences-in-november.md)
- [Global AI Protein Design Market Report 2026-2033 | Generative AI Fuels 35.3% CAGR and a $20.9 Billion Biologics Opportunity by 2033](https://biotechnews.io/news/global-ai-protein-design-market-report-2026-2033-generative-ai-fuels-35-3-cagr-and-a-20-9.md)
- [COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering](https://biotechnews.io/news/cosciens-biopharma-inc-reports-q3-2026-results-and-provides-update-on-convertible-debentur.md)
- [Biorisk Management Service Market Size to Reach USD 4.91 Billion by 2033, Growing at 11.4% CAGR as Regulatory Compliance and Risk Assessment Demand Accelerates: Verified Market Research](https://biotechnews.io/news/biorisk-management-service-market-size-to-reach-usd-4-91-billion-by-2033-growing-at-11-4-c.md)